Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC

Wayne Kuznar
Published: Sunday, Feb 16, 2020
Shilpa Gupta, MD, MBBS

Shilpa Gupta, MD

The neoadjuvant regimen of nivolumab (Opdivo) combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response (pCR) rate of 49% in patients with muscle-invasive bladder cancer, according to phase II results presented at the 2020 Genitourinary Cancers Symposium.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x